Serum β2-Microglobulin Predicts Time to Recovery of Delayed Graft Function in Kidney Transplant Recipients.
Humans
Kidney Transplantation
/ adverse effects
Delayed Graft Function
/ blood
Female
Male
beta 2-Microglobulin
/ blood
Middle Aged
Prognosis
Biomarkers
/ blood
Follow-Up Studies
Graft Survival
Glomerular Filtration Rate
Adult
Risk Factors
Graft Rejection
/ etiology
Kidney Failure, Chronic
/ surgery
Recovery of Function
Kidney Function Tests
Postoperative Complications
/ blood
Time Factors
Transplant Recipients
/ statistics & numerical data
DGF
recovery
serum β2‐microglobulin
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
revised:
05
08
2024
received:
21
06
2024
accepted:
07
08
2024
medline:
19
8
2024
pubmed:
19
8
2024
entrez:
19
8
2024
Statut:
ppublish
Résumé
Delayed graft function (DGF) after kidney transplantation is associated with adverse patients and allograft outcomes. A longer duration of DGF is predictive of worse graft outcomes compared to a shorter duration. Posttransplant serum β2-microglobulin (B2M) is associated with long-term graft outcomes, but its relationship with DGF recovery is unknown. We included all kidney-only transplant recipients with DGF enrolled in the E-DGF trial. Duration of DGF was defined as the interval between the transplant and the last dialysis session. We analyzed the association of standardized serum creatinine (Scr) and B2M on postoperative Days (POD) 1-7 during the subsequent days of DGF with the recovery of DGF. A total of 97 recipients with DGF were included. The mean duration of DGF was 11.0 ± 11.2 days. Higher Scr was not associated with the duration of DGF in unadjusted or adjusted models. Higher standardized B2M, in contrast, was associated with a prolonged duration of DGF. This association remained in models adjusting for baseline characteristics from POD 2 (3.19 days longer, 95% CI: 0.46-5.93; p = 0.02) through Day 6 of DGF (4.97 days longer, 95% CI: 0.75-9.20; p = 0.02). There was minimal change in mean Scr (0.01 ± 0. 10 mg/dL per day; p = 0.32), while B2M significantly decreased as the time to recovery approached (-0.14 ± 0.05 mg/L per day; p = 0.006), among recipients with DGF. B2M is more strongly associated with DGF recovery than Scr. Posttransplant B2M may be an important biomarker to monitor during DGF. ClinicalTrials.gov identifier: NCT03864926.
Sections du résumé
BACKGROUND
BACKGROUND
Delayed graft function (DGF) after kidney transplantation is associated with adverse patients and allograft outcomes. A longer duration of DGF is predictive of worse graft outcomes compared to a shorter duration. Posttransplant serum β2-microglobulin (B2M) is associated with long-term graft outcomes, but its relationship with DGF recovery is unknown.
METHODS
METHODS
We included all kidney-only transplant recipients with DGF enrolled in the E-DGF trial. Duration of DGF was defined as the interval between the transplant and the last dialysis session. We analyzed the association of standardized serum creatinine (Scr) and B2M on postoperative Days (POD) 1-7 during the subsequent days of DGF with the recovery of DGF.
RESULTS
RESULTS
A total of 97 recipients with DGF were included. The mean duration of DGF was 11.0 ± 11.2 days. Higher Scr was not associated with the duration of DGF in unadjusted or adjusted models. Higher standardized B2M, in contrast, was associated with a prolonged duration of DGF. This association remained in models adjusting for baseline characteristics from POD 2 (3.19 days longer, 95% CI: 0.46-5.93; p = 0.02) through Day 6 of DGF (4.97 days longer, 95% CI: 0.75-9.20; p = 0.02). There was minimal change in mean Scr (0.01 ± 0. 10 mg/dL per day; p = 0.32), while B2M significantly decreased as the time to recovery approached (-0.14 ± 0.05 mg/L per day; p = 0.006), among recipients with DGF.
CONCLUSION
CONCLUSIONS
B2M is more strongly associated with DGF recovery than Scr. Posttransplant B2M may be an important biomarker to monitor during DGF.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov identifier: NCT03864926.
Substances chimiques
beta 2-Microglobulin
0
Biomarkers
0
Banques de données
ClinicalTrials.gov
['NCT03864926']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15435Subventions
Organisme : Virginia Lee Cook Foundation
Informations de copyright
© 2024 The Author(s). Clinical Transplantation published by Wiley Periodicals LLC.
Références
D. Bahl, Z. Haddad, A. Datoo, and Y. A. Qazi, “Delayed Graft Function in Kidney Transplantation,” Current Opinion in Organ Transplantation 24 (2019): 82–86.
A. Siedlecki, W. Irish, and D. C. Brennan, “Delayed Graft Function in the Kidney Transplant,” American Journal of Transplantation 11 (2011): 2279–2296.
I. Helantera, H. N. Ibrahim, M. Lempinen, and P. Finne, “Donor Age, Cold Ischemia Time, and Delayed Graft Function,” Clinical Journal of the American Society of Nephrology 15 (2020): 813–821.
A. O. Ojo, R. A. Wolfe, P. J. Held, F. K. Port, and R. L. Schmouder, “Delayed Graft Function: Risk Factors and Implications for Renal Allograft Survival,” Transplantation 63 (1997): 968–974.
S. N. Tapiawala, K. J. Tinckam, C. J. Cardella, et al., “Delayed Graft Function and the Risk for Death With a Functioning Graft,” Journal of the American Society of Nephrology 21 (2010): 153–161.
S. G. Yarlagadda, S. G. Coca, R. N. Formica, Jr., E. D. Poggio, and C. R. Parikh, “Association Between Delayed Graft Function and Allograft and Patient Survival: A Systematic Review and Meta‐Analysis,” Nephrology, Dialysis, Transplantation 24 (2009): 1039–1047.
D. Incerti, N. Summers, T. G. N. Ton, A. Boscoe, A. Chandraker, and W. Stevens, “The Lifetime Health Burden of Delayed Graft Function in Kidney Transplant Recipients in the United States,” MDM Policy & Practice 3 (2018): 2381468318781811.
M. S. Helfer, J. C. Pompeo, O. R. S. Costa, A. R. Vicari, A. R. Ribeiro, and R. C. Manfro, “Long‐Term Effects of Delayed Graft Function Duration on Function and Survival of Deceased Donor Kidney Transplants,” Jornal Brasileiro De Nefrologia: orgao Oficial De Sociedades Brasileira e Latino‐Americana De Nefrologia 41 (2019): 231–241.
C. V. Donnelly, M. Keller, and L. Kayler, “Kidney Transplant Outcomes After Prolonged Delayed Graft Function,” Journal of Clinical Medicine 11 (2022): 1535.
M. Giral‐Classe, M. Hourmant, D. Cantarovich, et al., “Delayed Graft Function of More Than Six Days Strongly Decreases Long‐Term Survival of Transplanted Kidneys,” Kidney International 54 (1998): 972–978.
W. H. Lim, D. W. Johnson, A. Teixeira‐Pinto, and G. Wong, “Association Between Duration of Delayed Graft Function, Acute Rejection, and Allograft Outcome After Deceased Donor Kidney Transplantation,” Transplantation 103 (2019): 412–419.
C. Moers, J. M. Smits, M. H. Maathuis, et al., “Machine Perfusion or Cold Storage in Deceased‐Donor Kidney Transplantation,” New England Journal of Medicine 360 (2009): 7–19.
B. Nashan, M. Abbud‐Filho, and F. Citterio, “Prediction, Prevention, and Management of Delayed Graft Function: Where Are We Now?” Clinical Transplantation 30 (2016): 1198–1208.
A. G. Assounga, “Beta 2 Microglobulin in Kidney Failure: A Review and an Algorithm for Renal Replacement Therapy,” Saudi Journal of Kidney Diseases and Transplantation 32 (2021): 1214–1220.
X. Liu, M. C. Foster, H. Tighiouart, et al., “Non‐GFR Determinants of Low‐Molecular‐Weight Serum Protein Filtration Markers in CKD,” American Journal of Kidney Diseases 68 (2016): 892–900.
A. Mumtaz, M. Anees, M. Bilal, and M. Ibrahim, “Beta‐2 Microglobulin Levels in Hemodialysis Patients,” Saudi Journal of Kidney Diseases and Transplantation 21 (2010): 701–706.
S. Parajuli, B. Muth, M. Bloom, et al., “A Randomized Controlled Trial of Envarsus versus Immediate Release Tacrolimus in Kidney Transplant Recipients With Delayed Graft Function,” Transplantation Proceedings 55 (2023): 1568–1574.
B. L. Muth, B. C. Astor, J. Turk, et al., “Outpatient Management of Delayed Graft Function Is Associated With Reduced Length of Stay Without an Increase in Adverse Events,” American Journal of Transplantation 16 (2016): 1604–1611.
J. W. Blazel, J. A. Turk, B. L. Muth, and S. Parajuli, “Blessing and a Curse of Outpatient Management of Delayed Graft Function,” World Journal of Transplantation 9 (2019): 58–61.
S. Parajuli, E. Joachim, S. Alagusundaramoorthy, et al., “Subclinical Antibody‐Mediated Rejection After Kidney Transplantation: Treatment Outcomes,” Transplantation 103 (2019): 1722–1729.
J. Lee, S. H. Song, J. Y. Lee, et al., “The Recovery Status From Delayed Graft Function Can Predict Long‐Term Outcome After Deceased Donor Kidney Transplantation,” Scientific Reports 7 (2017): 13725.
N. Perico, D. Cattaneo, M. H. Sayegh, and G. Remuzzi, “Delayed Graft Function in Kidney Transplantation,” Lancet 364 (2004): 1814–1827.
C. Y. Hsu, G. M. Chertow, C. E. McCulloch, D. Fan, J. D. Ordoñez, and A. S. Go, “Nonrecovery of Kidney Function and Death After Acute on Chronic Renal Failure,” Clinical Journal of the American Society of Nephrology 4 (2009): 891–898.
J. J. Renkens, M. M. Rouflart, M. H. Christiaans, E. M. van den Berg‐Loonen, J. P. van Hooff, and L. W. van Heurn, “Outcome of Nonheart‐Beating Donor Kidneys With Prolonged Delayed Graft Function After Transplantation,” American Journal of Transplantation 5 (2005): 2704–2709.
J. Domínguez, F. Lira, R. Rebolledo, et al., “Duration of Delayed Graft Function Is an Important Predictor of 1‐Year Serum Creatinine,” Transplantation Proceedings 41 (2009): 131–132.
C. Marek, B. Thomson, A. Shoker, P. P. Luke, and M. A. Moser, “The Prognostic Value of Time Needed on Dialysis in Patients With Delayed Graft Function,” Nephrology, Dialysis, Transplantation 29 (2014): 203–208.
D. H. Mallon, D. M. Summers, J. A. Bradley, and G. J. Pettigrew, “Defining Delayed Graft Function After Renal Transplantation: Simplest Is Best,” Transplantation 96 (2013): 885–889.
K. J. Swanson, W. Zhong, D. A. Mandelbrot, and S. Parajuli, “Histopathological Features and Role of Allograft Kidney Biopsy Among Recipients With Prolonged Delayed Graft Function: A Review,” Transplantation (2024), https://doi.org/10.1097/TP.0000000000004928.
J. Malyszko, E. Lukaszyk, I. Glowinska, and M. Durlik, “Biomarkers of Delayed Graft Function as a Form of Acute Kidney Injury in Kidney Transplantation,” Scientific Reports 5 (2015): 11684.
S. S. Waikar, R. A. Betensky, and J. V. Bonventre, “Creatinine as the Gold Standard for Kidney Injury Biomarker Studies?” Nephrology, Dialysis, Transplantation 24 (2009): 3263–3265.
S. S. Waikar, R. A. Betensky, S. C. Emerson, and J. V. Bonventre, “Imperfect Gold Standards for Kidney Injury Biomarker Evaluation,” Journal of the American Society of Nephrology 23 (2012): 13–21.
G. L. Myers, W. G. Miller, J. Coresh, et al., “Recommendations for Improving Serum Creatinine Measurement: A Report From the Laboratory Working Group of the National Kidney Disease Education Program,” Clinical Chemistry 52 (2006): 5–18.
S. W. Cha, I. S. Shin, D. G. Kim, et al., “Effectiveness of Serum Beta‐2 Microglobulin as a Tool for Evaluating Donor Kidney Status for Transplantation,” Scientific Reports 10 (2020): 8109.
A. V. Trailin, M. V. Pleten, T. I. Ostapenko, N. F. Iefimenko, and O. S. Nikonenko, “High Serum Level of β2‐Microglobulin in Late Posttransplant Period Predicts Subsequent Decline in Kidney Allograft Function: A Preliminary Study,” Disease Markers 2015 (2015): 562580.
M. C. Foster, D. E. Weiner, A. G. Bostom, et al., “Filtration Markers, Cardiovascular Disease, Mortality, and Kidney Outcomes in Stable Kidney Transplant Recipients: the FAVORIT Trial,” American Journal of Transplantation 17 (2017): 2390–2399.
B. C. Astor, B. Muth, D. B. Kaufman, J. D. Pirsch, R. Michael Hofmann, and A. Djamali, “Serum β2‐Microglobulin at Discharge Predicts Mortality and Graft Loss Following Kidney Transplantation,” Kidney International 84 (2013): 810–817.
K. T. Woo, E. J. Lee, Y. K. Lau, and C. H. Lim, “Beta‐2‐Microglobulin in the Assessment of Renal Function of the Transplanted Kidney,” Nephron 39 (1985): 223–227.